US2023087443A1PendingUtilityA1

Enhancement of cd47 blockade therapy by proteasome inhibitors

55
Assignee: PF ARGENTUM IP HOLDINGS LLCPriority: Nov 3, 2016Filed: Aug 17, 2022Published: Mar 23, 2023
Est. expiryNov 3, 2036(~10.3 yrs left)· nominal 20-yr term from priority
Inventors:Emma LinderothNatasja Nielsen VillerRobert Adam UgerPenka Slavcheva Slavova-Petrova
C07F 5/025A61P 35/02A61K 38/05C07F 5/04A61K 38/005A61P 35/00C07K 16/2803A61K 31/69C07K 14/705C07K 2319/30A61K 38/00A61K 38/07C07K 7/06A61K 38/177A61K 38/08A61K 47/6811C07K 14/70596A61K 31/5355A61K 47/68C07K 16/00A61K 38/17
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

Claims

exact text as granted — not AI-modified
1 . A use of a combination of a CD47 blockade drug and a proteasome inhibitor for treating a subject with CD47+ disease cells. 
     
     
         2 . The use according to  claim 1 , wherein the proteasome inhibitor is selected from an epoxyketone and a boronate. 
     
     
         3 . The use according to  claim 2 , wherein the proteasome inhibitor is a boronate. 
     
     
         4 . The use according to  claim 3 , wherein the inhibitor is bortezomib. 
     
     
         5 . The use according to  claim 3 , wherein the inhibitor is ixazomib. 
     
     
         6 . The use according to  claim 2 , wherein the proteasome inhibitor is an epoxyketone. 
     
     
         7 . The use according to  claim 5 , wherein the proteasome inhibitor is carfilzomib. 
     
     
         8 . The use according to  claim 5 , wherein the inhibitor is a fluorinated carfilzomib analog. 
     
     
         9 - 47 . (canceled)

Join the waitlist — get patent alerts

Track US2023087443A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.